on ONXEO (EPA:ALONX)
Valerio Therapeutics Partners with Abivax for RNA Therapeutics Development
Valerio Therapeutics has signed a binding term-sheet for a collaborative venture with Abivax, aiming to advance research and development in RNA therapeutics. The agreement promises an upfront payment of up to €2.4 million to Valerio, alongside potential milestone payments and royalties, contingent on a definitive agreement.
The partnership seeks to create innovative therapeutic candidates targeting immune-mediated inflammatory diseases. Combining Valerio's platform with Abivax's expertise, the collaboration will oversee the generation and evaluation of candidates, potentially leading to further development by Abivax.
Valerio aims to push pipeline advancement, highlighting progressed candidates like VTX-001 and VTX-002. The collaboration aligns with Valerio's strategic focus on partnering to maximize its technological capabilities.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ONXEO news